Kestra Medical Technologies, Ltd. (KMTS)
| Market Cap | 1.61B +41.9% |
| Revenue (ttm) | 106.73M +60.7% |
| Net Income | -149.87M |
| EPS | -2.68 |
| Shares Out | 59.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,774 |
| Open | 27.00 |
| Previous Close | 26.91 |
| Day's Range | 26.43 - 27.27 |
| 52-Week Range | 17.34 - 30.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.29 (+12.31%) |
| Earnings Date | Sep 14, 2026 |
About KMTS
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverte... [Read more]
Financial Performance
In fiscal year 2026, KMTS's revenue was $95.13 million, an increase of 59.03% compared to the previous year's $59.82 million. Losses were -$131.61 million, 4.34% more than in 2025.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KMTS stock is "Buy." The 12-month stock price target is $30.29, which is an increase of 12.31% from the latest price.
News
Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on ...
Kestra Medical down 7% at $22.32 after Q1 earnings miss
16:35 EDT Kestra Medical (KMTS) down 7% at $22.32 after Q1 earnings miss
Kestra Medical Technologies Earnings Call Transcript: Q1 2027
Revenue grew 60% YoY to $31M with gross margin expanding to 56.5%, driven by higher in-network mix and cost improvements. FY 2027 revenue guidance was raised to $141M (48% growth), with gross margin targets increased to mid-70% over the next few years.
Kestra Medical Technologies Earnings release: Q1 2027
Kestra Medical Technologies released its Q1 2027 earnings on September 14, 2026, summarizing the period's financial results.
Kestra Medical Technologies Quarterly report: Q1 2027
Kestra Medical Technologies has published its Q1 2027 quarterly earnings report on September 14, 2026.
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results...
Kestra Medical Technologies Slides: Corporate presentation
Kestra Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on September 11, 2026.
Kestra Names Daniel Finney Vice President of Research & Development
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finn...
Kestra Medical Technologies Transcript: AGM 2026
The meeting covered the election of three directors and ratification of PwC as auditor, both of which passed. No shareholder questions were received, and final voting results will be filed in a Form 8-K.
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
KIRKLAND, Wash., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report first quar...
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment o...
Kestra Medical initiated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus initiated coverage of Kestra Medical (KMTS) with an Overweight rating and $30 price target Kestra is a commercial-stage wearable medical device and digital health compan...
Kestra Medical Technologies Proxy statement: Proxy filing
Kestra Medical Technologies filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Kestra Medical Technologies Proxy statement: Proxy filing
Kestra Medical Technologies filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Kestra Medical initiated with a Perform at Oppenheimer
Oppenheimer initiated coverage of Kestra Medical (KMTS) with a Perform rating and no price target The firm is bullish on the company’s fundamentals but prefers a better entry point into…
Kestra Medical price target raised to $32 from $30 at BTIG
BTIG raised the firm’s price target on Kestra Medical (KMTS) to $32 from $30 and keeps a Buy rating on the shares. The company’s Q4 revenue beat was driven by…
Kestra Medical Technologies Earnings Call Transcript: Q4 2026
Revenue grew 66% in Q4 and 59% for FY 2026, with gross margin expanding over 10 points year-over-year. FY 2027 guidance targets 44% revenue growth and further margin improvement, driven by sales force expansion, clinical evidence, and operational leverage.
Kestra Medical Technologies Earnings release: Q4 2026
Kestra Medical Technologies released its Q4 2026 earnings on July 14, 2026, summarizing the period's financial results.
Kestra Medical Technologies Annual report: Q4 2026
Kestra Medical Technologies has published its Q4 2026 annual report on July 14, 2026.
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it has enter...
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results ...
Kestra Medical Technologies Slides: Company presentation
Kestra Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth qua...
Kestra Medical Technologies Transcript: Bank of America Global Healthcare Conference 2026
Strong FY 2026 momentum was driven by expanded payer coverage and a larger, more productive sales force, resulting in rapid market share gains and robust revenue growth. Clinical data and innovation are expected to drive further market expansion, margin improvement, and new product launches, with partnerships like Biobeat enhancing future revenue opportunities.
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
KIRKLAND, Wash., April 29, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.